Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker

  • Wang R
  • Li X
  • Zhang H
  • et al.
N/ACitations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

// Ru Wang 1 , Xiao Li 1 , Huimin Zhang 1 , Ke Wang 1 and Jianjun He 1 1 Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, P.R. China Correspondence to: Jianjun He, email: chinahjj@163.com Keywords: biomarker, liquid biopsy, ctDNA, breast cancer Received: May 09, 2017      Accepted: August 17, 2017      Published: September 01, 2017 ABSTRACT Circulating tumor DNA (ctDNA) in the blood of cancer patients contains much information on genetic and epigenetic profiles associated with cancer development, progression, and response to therapy. Analysis of ctDNA provides an opportunity for non-invasive sampling of tumor DNA repetitiously and therefore advance precision medicine. Recent development in massively parallel sequencing and digital genomic techniques support the analytical and clinical validity of ctDNA as a promising ‘liquid biopsy’ in human cancer. In this review, we discussed the current status of cell-free ctDNA including ctDNA biology, recently developed techniques for ctDNA detection, breast cancer specific detecting strategies, with a focus on clinical applications of ctDNA-based biomarkers in breast oncology.

Cite

CITATION STYLE

APA

Wang, R., Li, X., Zhang, H., Wang, K., & He, J. (2017). Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker. Oncotarget, 8(43). https://doi.org/10.18632/oncotarget.20608

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free